Abstract: Novel technology for RNA synthesis in the reverse direction, involving a new class of products, 3?-DMT-5’-CE ribonucleoside phosphoramidites and 3?-DMT-5’-succinyl ribonucleoside solid supports, with per step coupling efficiency surpassing 99% in the RNA synthesis. This leads to high purity RNA. Examples of a large number of 20-21 mers and a few examples of long chain oligonucleotides are demonstrated. The data indicates dramatic improvement in coupling efficiency per step during oligonucleotide synthesis using the reverse RNA monomers (5??? direction) as compared to 3?-CE ribonucleoside phosphoramidites used in the conventional method of RNA synthesis (3??5? direction). The new process requires shorter coupling cycle time, approx. 4 minutes as compared to approx. 10 minutes using conventional RNA synthesis method (3??5? direction). Furthermore, almost complete absence of M+1 impurities in the reverse RNA synthesis methodology were observed, even when the last phosphoramidite was a macromolecule.

Abstract: The invention provides compositions for and methods of treating a number of disorders. In one embodiment, the invention provides a method of treating a wide range of conditions by administering to a human being in need of such treatment, a therapeutically effective amount of (a) N-6-trimethyl-L-lysine of at least 98% purity, (b) a prodrug thereof, (c) an aliphatic chain derivative thereof, (d) an ester derivative thereof, (e) an amide derivative thereof, or (f) a pharmaceutically acceptable salt of said N-6-trimethyl-L-lysine or said prodrug.

Abstract: The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least two CpG dinucleotides and a prodrug of an antimetabolite. The prodrug can be part of a CpG dinucleotide or may be attached elsewhere on the oligonucleotide.